Views & Analysis Addressing MS’ two-tier healthcare system is about ‘social j... NICE has reversed its decision not to approve a new drug that offers hope to thousands o
News Roche’s MS drug Ocrevus earns blockbuster status a year afte... Roche’s multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has claimed blockbuster status just one year after it was launched.
News Roche’s MS drug Ocrevus nears European market Roche's new multiple sclerosis drug Ocrevus (ocrelizumab) gained FDA approval in March, and since then has achieved remarkable revenues of half a billion dollars in the year to date.<
News Brain infection would be bad news for Roche's MS drug Ocrevu... Suggestion is that PML case was caused by previous treatment.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
